Acute Hyperinsulinemia during Hyperinsulinemic- Euglycemic Clamp Influences DNA Methylation and Gene Expression in Peripheral Blood Cells of Adult Men.

EpigenomicsVol. 7, No. 8 CommentaryMendelian randomization: applications and limitations in epigenetic studiesCaroline L Relton & George Davey SmithCaroline L Relton*Author for correspondence: E-mail Address: caroline.relton@bristol.ac.uk MRC Integrative Epidemiology Unit, University of Bristol, Bristol, BS8 2BN, UK & George Davey Smith MRC Integrative Epidemiology Unit, University of Bristol, Bristol, BS8 2BN, UKPublished Online:7 Dec 2015https://doi.org/10.2217/epi.15.88AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: causal inferenceDNA methylationepidemiologyepigeneticsmediationSNPPapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1 Mathers JC, Strathdee G, Relton CL. Induction of epigenetic alterations by dietary and other environmental factors. Adv. Genet. 71, 3–39 (2010).Crossref, Medline, Google Scholar2 Cortessis VK1, Thomas DC, Levine AJ et al. Environmental epigenetics: prospects for studying epigenetic mediation of exposure–response relationships. Hum. Genet. 131, 1565–1589 (2012).Crossref, Medline, CAS, Google Scholar3 Barrow TM, Michels KB. Epigenetic epidemiology of cancer. Biochem. Biophys. Res. Commun. 455, 70–83 (2014).Crossref, Medline, CAS, Google Scholar4 Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol. 8, 1056–1072 (2009).Crossref, Medline, CAS, Google Scholar5 Dick KJ, Nelson CP, Tsaprouni L et al. DNA methylation and body-mass index: a genome-wide analysis. Lancet 383, 1990–1998 (2014).Crossref, Medline, CAS, Google Scholar6 Liang L, Willis-Owen SA, Laprise C et al. An epigenome-wide association study of total serum immunoglobulin E concentration. Nature 520(7549), 670–674 (2015).• The first major epigenome-wide association study to implement formal Mendelian randomization.Crossref, Medline, CAS, Google Scholar7 Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32, 1–22 (2003).•• Details the application of Mendelian randomization.Crossref, Medline, Google Scholar8 Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum. Mol. Genet. 23(R1), R89–R98 (2014).•• Recent developments and refinements in the application of Mendelian randomization.Crossref, Medline, CAS, Google Scholar9 Greenland S. An introduction to instrumental variables for epidemiologists. Int. J. Epidemiol. 29, 722–729 (2000).Crossref, Medline, CAS, Google Scholar10 Sheehan NA, Didelez V, Burton PR, Tobin MD. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med. 5, e177 (2008).Crossref, Medline, Google Scholar11 Jansen RC, Nap JP. Genetical genomics: the added value from segregation. Trends Genet. 17, 388–391 (2001).Crossref, Medline, CAS, Google Scholar12 Schadt EE, Lamb J, Yang X et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat. Genet. 37, 710–717 (2005).Crossref, Medline, CAS, Google Scholar13 Liu Y, Aryee MJ, Padyukov L et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat. Biotechnol. 31, 142–147 (2013).Crossref, Medline, CAS, Google Scholar14 Blakely T, McKenzie S, Carter K. Misclassification of the mediator matters when estimating indirect effects. J. Epidemiol. Community Health 67, 458–466 (2013).Crossref, Medline, Google Scholar15 Relton CL, Davey Smith G. Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease. Int. J. Epidemiol. 41, 161–176 (2012).•• Outlines the application of Mendelian randomization to epigenetics to strengthen causal inference.Crossref, Medline, Google Scholar16 Zhang D, Cheng L, Badner JA et al. Genetic control of individual differences in gene-specific methylation in human brain. Am. J. Hum. Genet. 86, 411–419 (2010).Crossref, Medline, CAS, Google Scholar17 Bell JT, Pai AA, Pickrell JK et al. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 12, R10 (2011).Crossref, Medline, CAS, Google Scholar18 Timofeeva MN, McKay JD, Davey Smith G et al. Genetic Polymorphisms in 15q25 and 19q13 loci, cotinine levels, and risk of lung cancer in EPIC. Cancer Epidemiol. Biomarkers Prev. 20, 2250–2261 (2011).Crossref, Medline, CAS, Google Scholar19 Zuccolo L, Fitz-Simon N, Gray R et al. A non-synonymous variant in ADH1B is strongly associated with prenatal alcohol use in a European sample of pregnant women. Hum. Mol. Genet. 18, 4457–4466 (2009).Crossref, Medline, CAS, Google Scholar20 Timpson NJ, Harbord R, Davey Smith G, Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. Does greater adiposity increase blood pressure and hypertension risk? Mendelian randomization using the FTO/MC4R genotype. Hypertension 54, 84–90 (2009).Crossref, Medline, CAS, Google Scholar21 Benn M, Tybjaerg-Hansen A, Stender S, Frikke-Schmidt R, Nordestgaard BG. Low-density lipoprotein cholesterol and the risk of cancer: a Mendelian randomization study. J. Natl Cancer Inst. 103, 508–519 (2011).Crossref, Medline, CAS, Google Scholar22 Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wide association studies for common human diseases. Nat. Rev. Genet. 12, 529–541 (2011).Crossref, Medline, CAS, Google Scholar23 Shi J, Marconett CN, Duan J et al. Characterizing the genetic basis of methylome diversity in histologically normal human lung tissue. Nat. Commun. 5, 3365 (2014).Crossref, Medline, Google Scholar24 Cole DA, Preacher KJ. Manifest variable path analysis: potentially serious and misleading consequences due to uncorrected measurement error. Psychol. Methods 19, 300–315 (2014).Crossref, Medline, Google Scholar25 Groom A, Potter C, Swan DC et al. Postnatal growth and DNA methylation are associated with differential gene expression of the TACSTD2 gene and childhood fat mass. Diabetes 61, 391–400 (2012).Crossref, Medline, CAS, Google Scholar26 Allard C, Desgagne V, Patenaude J et al. Mendelian randomization supports causality between maternal hyperglycaemia and epigenetic regulation of leptin gene in newborns. Epigenetics 10(4), 342–351 (2015).Crossref, Medline, CAS, Google Scholar27 Kirkbride J, Susser E, Kundakovic M, Kresovich JK, Davey Smith G, Relton CL. Prenatal nutrition, epigenetics and schizophrenia risk: can we test causal effects? Epigenomics 4(3), 303–315 (2012).Link, CAS, Google Scholar28 Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM. DNA methylation in white blood cells: association with risk factors in epidemiologic studies. Epigenetics 6, 828–837 (2011).Crossref, Medline, CAS, Google Scholar29 Zeilinger S, Kühnel B, Klopp N et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS ONE 8, e63812 (2013).Crossref, Medline, CAS, Google Scholar30 Maher B. ENCODE: the human encyclopaedia. Nature 489, 46–48 (2012).Crossref, Medline, Google Scholar31 Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44(2), 512–525 (2015).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByEpigenome-wide epidemiologic studies of human immunodeficiency virus infection, treatment, and disease progression11 January 2022 | Clinical Epigenetics, Vol. 14, No. 1A comparison of the genes and genesets identified by GWAS and EWAS of fifteen complex traits19 December 2022 | Nature Communications, Vol. 13, No. 1Prenatal medication exposure and epigenetic outcomes: a systematic literature review and recommendations for prenatal pharmacoepigenetic studies29 April 2021 | Epigenetics, Vol. 17, No. 4Shared Genetic Basis and Causal Relationship Between Television Watching, Breakfast Skipping and Type 2 Diabetes: Evidence From a Comprehensive Genetic Analysis24 March 2022 | Frontiers in Endocrinology, Vol. 13Epigenetic Clocks14 April 2022EpigeneticsImpact of In Utero Folate Exposure on DNA Methylation and Its Potential Relevance for Later‐Life Health—Evidence from Mouse Models Translated to Human Cohorts13 December 2021 | Molecular Nutrition & Food Research, Vol. 261A meta-analysis of epigenome-wide association studies in Alzheimer's disease highlights novel differentially methylated loci across cortex10 June 2021 | Nature Communications, Vol. 12, No. 1Genetic impacts on DNA methylation: research findings and future perspectives30 April 2021 | Genome Biology, Vol. 22, No. 1Causal Inference Methods to Integrate Omics and Complex Traits17 August 2020 | Cold Spring Harbor Perspectives in Medicine, Vol. 11, No. 5Tobacco Smoking and the Association With First Incidence of Mood, Anxiety, and Substance Use Disorders: A 3-Year Prospective Population-Based Study15 March 2021 | Clinical Psychological Science, Vol. 9, No. 3Time trends in epigenetic signatures and population health risksInvited Review – A 5‐year update on epigenome‐wide association studies of DNA modifications in Alzheimer's disease: progress, practicalities and promise30 August 2020 | Neuropathology and Applied Neurobiology, Vol. 46, No. 7Understanding the Interplay Between Health Disparities and Epigenomics20 August 2020 | Frontiers in Genetics, Vol. 11Lifetime Smoking and Asthma: A Mendelian Randomization Study4 August 2020 | Frontiers in Genetics, Vol. 11Genetically, Dietary Sodium Intake Is Causally Associated with Salt-Sensitive Hypertension Risk in a Community-Based Cohort Study: a Mendelian Randomization Approach26 June 2020 | Current Hypertension Reports, Vol. 22, No. 7Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic ReviewPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Vol. 40, No. 4Epigenetics and gestational diabetes: a review of epigenetic epidemiology studies and their use to explore epigenetic mediation and improve prediction17 October 2019 | Diabetologia, Vol. 62, No. 12DNA methylation aging clocks: challenges and recommendations25 November 2019 | Genome Biology, Vol. 20, No. 1Mendelian randomization provides support for obesity as a risk factor for meningioma22 January 2019 | Scientific Reports, Vol. 9, No. 1Appraising the causal relevance of DNA methylation for risk of lung cancer24 September 2019 | International Journal of Epidemiology, Vol. 48, No. 5Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations17 May 2019 | Science China Life Sciences, Vol. 62, No. 6A brief tour of epidemiologic epigenetics and mental healthCurrent Opinion in Psychology, Vol. 27An integrative approach to detect epigenetic mechanisms that putatively mediate the influence of lifestyle exposures on disease susceptibility29 June 2019 | International Journal of Epidemiology, Vol. 48, No. 3Causal Modeling in Environmental HealthAnnual Review of Public Health, Vol. 40, No. 1Mendelian Randomization and the Environmental Epigenetics of Health: a Systematic Review18 February 2019 | Current Environmental Health Reports, Vol. 6, No. 1Postnatal Social Factors: The Epigenome and the Skeleton29 June 2019Epigenomics in tobacco risk assessment: Opportunities for integrated new approachesCurrent Opinion in Toxicology, Vol. 11-12Unravelling the Roles of Susceptibility Loci for Autoimmune Diseases in the Post-GWAS Era27 July 2018 | Genes, Vol. 9, No. 8DNA methylation in human lipid metabolism and related diseasesCurrent Opinion in Lipidology, Vol. 29, No. 2Protocol for the EMPHASIS study; epigenetic mechanisms linking maternal pre-conceptional nutrition and children's health in India and Sub-Saharan Africa30 October 2017 | BMC Nutrition, Vol. 3, No. 1Epigenetics and noncommunicable diseasesGemma C Sharp & Caroline L Relton19 May 2017 | Epigenomics, Vol. 9, No. 6Role of DNA Methylation in Type 2 Diabetes Etiology: Using Genotype as a Causal Anchor28 February 2017 | Diabetes, Vol. 66, No. 6'Mendelian randomization': an approach for exploring causal relations in epidemiologyPublic Health, Vol. 145Small-Magnitude Effect Sizes in Epigenetic End Points are Important in Children's Environmental Health Studies: The Children's Environmental Health and Disease Prevention Research Center's Epigenetics Working GroupEnvironmental Health Perspectives, Vol. 125, No. 4Epigenetic dysregulation of brainstem nuclei in the pathogenesis of Alzheimer's disease: looking in the correct place at the right time?14 September 2016 | Cellular and Molecular Life Sciences, Vol. 74, No. 3Association of Body Mass Index with DNA Methylation and Gene Expression in Blood Cells and Relations to Cardiometabolic Disease: A Mendelian Randomization Approach17 January 2017 | PLOS Medicine, Vol. 14, No. 1Early Life Exposures and Adult Cancer Risk12 April 2017 | Epidemiologic Reviews, Vol. 39, No. 1Identification and validation of seven new loci showing differential DNA methylation related to serum lipid profile: an epigenome-wide approach. The REGICOR study15 September 2016 | Human Molecular Genetics, Vol. 25, No. 20How to make DNA methylome wide association studies more powerfulXinyi Lin, Sheila Barton & Joanna D Holbrook7 April 2016 | Epigenomics, Vol. 8, No. 8 Vol. 7, No. 8 Follow us on social media for the latest updates Metrics Downloaded 297 times History Published online 7 December 2015 Published in print December 2015 Information© Future Medicine LtdKeywordscausal inferenceDNA methylationepidemiologyepigeneticsmediationSNPAcknowledgementsThe authors would like to thank members of the MRC Integrative Epidemiology Unit for their contribution in developing this area of research.Financial & competing interests disclosuresThe authors' work related to the application of Mendelian randomization to epigenetics is supported by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol (MC_UU_12013/1 and MC_UU_12013/2). This work was also supported by CRUK (grant number C18281/A19169). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download

BackgroundMarijuana’s putative anti-inflammatory properties may benefit HIV-associated comorbidities. How recreational marijuana use affects gene expression in peripheral blood cells (PBC) among youth with HIV-1 (YWH) is unknown.ApproachYWH with defined substance use (n = 54) receiving similar antiretroviral therapy (ART) were assigned to one of four analysis groups: YWH with detectable plasma HIV-1 (> 50 RNA copies/ml) who did not use substances (H+V+S−), and YWH with undetectable plasma HIV-1 who did not use substances (H+V−S−), or used marijuana alone (H+V−S+[M]), or marijuana in combination with tobacco (H+V−S+[M/T]). Non-substance using youth without HIV infection (H−S−, n = 25) provided a reference group. PBC mRNA was profiled by Affymetrix GeneChip Human Genome U133 Plus 2.0 Array. Differentially expressed genes (DEG) within outcome groups were identified by Significance Analysis of Microarrays and used for Hierarchical Clustering, Principal Component Analysis, and Ingenuity Pathways Analysis.ResultsHIV-1 replication resulted in > 3000 DEG involving 27 perturbed pathways. Viral suppression reduced DEG to 313, normalized all 27 pathways, and down-regulated two additional pathways, while marijuana use among virally suppressed YWH resulted in 434 DEG and no perturbed pathways. Relative to H+V−S−, multiple DEG normalized in H+V−S+[M]. In contrast, H+V−S+[M/T] had 1140 DEG and 10 dysregulated pathways, including multiple proinflammatory genes and six pathways shared by H+V+S−.ConclusionsYWH receiving ART display unique transcriptome bioprofiles based on viral replication and substance use. In the context of HIV suppression, marijuana use, alone or combined with tobacco, has opposing effects on inflammatory gene expression.

The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool

BackgroundThe link between DNA methylation, obesity, and adiposity-related diseases in the general population remains uncertain.Methods and FindingsWe conducted an association study of body mass index (BMI) and differential methylation for over 400,000 CpGs assayed by microarray in whole-blood-derived DNA from 3,743 participants in the Framingham Heart Study and the Lothian Birth Cohorts, with independent replication in three external cohorts of 4,055 participants. We examined variations in whole blood gene expression and conducted Mendelian randomization analyses to investigate the functional and clinical relevance of the findings. We identified novel and previously reported BMI-related differential methylation at 83 CpGs that replicated across cohorts; BMI-related differential methylation was associated with concurrent changes in the expression of genes in lipid metabolism pathways. Genetic instrumental variable analysis of alterations in methylation at one of the 83 replicated CpGs, cg11024682 (intronic to sterol regulatory element binding transcription factor 1 [SREBF1]), demonstrated links to BMI, adiposity-related traits, and coronary artery disease. Independent genetic instruments for expression of SREBF1 supported the findings linking methylation to adiposity and cardiometabolic disease. Methylation at a substantial proportion (16 of 83) of the identified loci was found to be secondary to differences in BMI. However, the cross-sectional nature of the data limits definitive causal determination.ConclusionsWe present robust associations of BMI with differential DNA methylation at numerous loci in blood cells. BMI-related DNA methylation and gene expression provide mechanistic insights into the relationship between DNA methylation, obesity, and adiposity-related diseases.

ObjectiveThis study employed bioinformatics techniques to identify diagnostic genes associated with programmed cell death (PCD) and to explore potential therapeutic agents for the treatment of sepsis.MethodsGene expression profiles from sepsis patients were analyzed to identify differentially expressed genes (DEGs) and hub genes through Weighted Gene Co-expression Network Analysis (WGCNA). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to elucidate the functions of the DEGs. PCD-related genes were cross-referenced with the identified DEGs. Diagnostic genes were selected using Least Absolute Shrinkage and Selection Operator (LASSO) and Random Forest (RF) methodologies. Single-cell RNA sequencing was utilized to assess gene expression in blood cells, while CIBERSORT was employed to evaluate immune cell infiltration. A transcription factor (TF)-microRNA (miRNA)-hub gene network was constructed, and potential therapeutic compounds were predicted using the Drug Gene Interaction Database (DGIdb). Mendelian Randomization (MR) methods were applied to analyze genome-wide association study (GWAS) data for S100A9, TXN, and GSTO1.ResultsThe analysis revealed 2156 PCD-related genes, 714 DEGs, and 1198 hub genes, with 88 genes enriched in immune and cell death pathways. Five pivotal PCD-related genes (IRAK3, S100A9, TXN, NFATC2, and GSTO1) were identified, leading to the construction of a network comprising six transcription factors and 171 microRNAs. Additionally, seven drugs targeting S100A9, TXN, and NFATC2 were identified. MR analysis suggested that a decrease in GSTO1 levels is associated with an increased risk of sepsis, and that sepsis influences the levels of S100A9, TXN, and GSTO1.ConclusionsThrough bioinformatics approaches, this study successfully identified five genes (IRAK3, S100A9, TXN, NFATC2, and GSTO1) associated with programmed cell death in the context of sepsis. This research identified seven candidate drugs for sepsis treatment and established a methodological framework for predicting biomarkers and drug targets that could be applicable to other diseases.

IntroductionIt is well known that chronic hyperglycemia or chronic inflammation leads to both FOXO1 and Ang-2 gene (ANGPT2) expression induction in endothelial cells. ANGPT2 and FOXO1 relative gene expression in peripheral blood cells in diabetes and myocardial ischemia were not researched extensively.AimOur objective was to evaluate ANGPT2 and FOXO1 gene expression in peripheral blood cells in patients with non-ST elevation myocardial infarction (NSTEMI), both with and without type 2 diabetes mellitus (T2DM), and compare them to the results obtained from T2DM and control subjects.Material and methodsThis was a multi-center, prospective study of 138 NSTEMI patients with/without T2DM, T2DM and a control group. FOXO1, ANGPT2, TBP (TATA box binding protein – as a reference gene) gene expression levels in peripheral blood cells were measured in each patient. Electrocardiography and echocardiography with assessment of ejection fraction (EF) were performed. Patients with NSTEMI underwent urgent (< 24 h) coronarography and the SYNTAX score and GRACE 2.0 score were calculated.ResultsThe ANGPT2 gene relative expression in buffy coat in the analyzed samples was very low and detectable only in 11 patients from all groups (8.66% of all patients). The level of FOXO1 gene relative expression was significantly higher in patients with NSTEMI (median relative expression = 1.39) than in non-NSTEMI patients (median = 1.09) (W = 1578, p < 0.05) regardless of the presence of T2DM. The FOXO1 gene relative expression was not correlated with GRACE 2.0 score or SYNTAX score of NSTEMI patients. We did not observe any significant change in FOXO1 gene expression after successful angioplasty.ConclusionsOn the basis of our results we can conclude that analyzing the ANGPT2 gene relative expression in peripheral blood cells has no role in assessment of CAD complexity among patients with and without T2DM. FOXO1 gene relative expression in blood peripheral cells is elevated in patients with NSTEMI regardless of the presence of T2DM. FOXO1 expression does not decrease after successful percutaneous coronary intervention and is not correlated with the severity of CAD in patients with NSTEMI.

Childhood maltreatment is likely to influence fundamental biological processes and engrave long-lasting epigenetic marks, leading to adverse health outcomes in adulthood. We aimed to elucidate the impact of different early environment on disease-related genome-wide gene expression and DNA methylation in peripheral blood cells in patients with posttraumatic stress disorder (PTSD). Compared with the same trauma-exposed controls (n = 108), gene-expression profiles of PTSD patients with similar clinical symptoms and matched adult trauma exposure but different childhood adverse events (n = 32 and 29) were almost completely nonoverlapping (98%). These differences on the level of individual transcripts were paralleled by the enrichment of several distinct biological networks between the groups. Moreover, these gene-expression changes were accompanied and likely mediated by changes in DNA methylation in the same loci to a much larger proportion in the childhood abuse (69%) vs. the non-child abuse-only group (34%). This study is unique in providing genome-wide evidence of distinct biological modifications in PTSD in the presence or absence of exposure to childhood abuse. The findings that nonoverlapping biological pathways seem to be affected in the two PTSD groups and that changes in DNA methylation appear to have a much greater impact in the childhood-abuse group might reflect differences in the pathophysiology of PTSD, in dependence of exposure to childhood maltreatment. These results contribute to a better understanding of the extent of influence of differences in trauma exposure on pathophysiological processes in stress-related psychiatric disorders and may have implications for personalized medicine.

BackgroundAdiponectin critically contributes to metabolic homeostasis, especially by insulin-sensitizing action. Gestational diabetes mellitus (GDM) is characterized by insulin resistance leading to materno-fetal hyperglycemia and detrimental birth outcomes. By investigating paired subcutaneous (SAT) and visceral adipose tissue (VAT) as well as blood (cell) samples of GDM-affected (n = 25) vs. matched control (n = 30) mother-child dyads of the prospective “EaCH” cohort study, we addressed whether alterations of adiponectin plasma, mRNA, and DNA methylation levels are associated with GDM and offspring characteristics.ResultsHypoadiponectinemia was present in women with GDM, even after adjustment for body mass index (BMI). This was accompanied by significantly decreased mRNA levels in both SAT and VAT (P < 0.05), independent of BMI. Maternal plasma adiponectin showed inverse relations with glucose and homeostatic model assessment of insulin resistance (both P < 0.01). In parallel to reduced mRNA expression in GDM, significant (P < 0.05) yet small alterations in locus-specific DNA methylation were observed in maternal fat (~ 2%) and blood cells (~ 1%). While newborn adiponectin levels were similar between groups, DNA methylation in GDM offspring was variously altered (~ 1–4%; P < 0.05).ConclusionsReduced adiponectin seems to be a pathogenic co-factor in GDM, even independent of BMI, affecting materno-fetal metabolism. While altered maternal DNA methylation patterns appear rather marginally involved, functional, diagnostic, and/or predictive implications of cord blood DNA methylation should be further evaluated.

A large-scale behavior of allelic dropout and imbalance caused by DNA methylation changes in an early-ripening bud sport of peach.

We previously reported the results of a randomized, open-label trial of egg oral immunotherapy (OIT) in 50 children where 44% were desensitized and 46% partially desensitized after 8 months of treatment. Here, we focus on cell-mediated molecular mechanisms driving desensitization during egg OIT. We sought to determine whether changes in genome-wide gene expression in blood cells during egg OIT correlate with humoral responses and the clinical outcome. The blood cell transcriptome of 50 children receiving egg OIT was profiled using peripheral blood mononuclear cell (PBMC) samples obtained at baseline and after 3 and 8 months of OIT. We identified 467 differentially expressed genes (DEGs) after 3 or 8 months of egg OIT. At 8 months, 86% of the DEGs were downregulated and played a role in the signaling of TREM1, IL-6, and IL-17. In correlation analyses, Gal d 1-4 –specific IgG4 antibodies associated positively with DEGs playing a role in pathogen recognition and antigen presentation, and negatively with DEGs playing a role in the signaling of IL-10, IL-6, and IL-17. Desensitized and partially desensitized patients had differences in their antibody responses, and although most of the transcriptomic changes were shared, both groups had also specific patterns, which suggest slower changes in partially desensitized and activation of NK cells in the desensitized group. OIT for egg allergy in children inhibits inflammation and activates innate immune responses regardless of the clinical outcome at 8 months. Changes in gene expression patterns first appear as posttranslational protein modifications, followed by more sustained epigenetic gene regulatory functions related to successful desensitization.

We previously reported the results of a randomized, open-label trial of egg oral immunotherapy (OIT) in 50 children where 44% were desensitized and 46% partially desensitized after 8 months of treatment. Here, we focus on cell-mediated molecular mechanisms driving desensitization during egg OIT. We sought to determine whether changes in genome-wide gene expression in blood cells during egg OIT correlate with humoral responses and the clinical outcome. The blood cell transcriptome of 50 children receiving egg OIT was profiled using peripheral blood mononuclear cell (PBMC) samples obtained at baseline and after 3 and 8 months of OIT. We identified 467 differentially expressed genes (DEGs) after 3 or 8 months of egg OIT. At 8 months, 86% of the DEGs were downregulated and played a role in the signaling of TREM1, IL-6, and IL-17. In correlation analyses, Gal d 1-4 –specific IgG4 antibodies associated positively with DEGs playing a role in pathogen recognition and antigen presentation, and negatively with DEGs playing a role in the signaling of IL-10, IL-6, and IL-17. Desensitized and partially desensitized patients had differences in their antibody responses, and although most of the transcriptomic changes were shared, both groups had also specific patterns, which suggest slower changes in partially desensitized and activation of NK cells in the desensitized group. OIT for egg allergy in children inhibits inflammation and activates innate immune responses regardless of the clinical outcome at 8 months. Changes in gene expression patterns first appear as posttranslational protein modifications, followed by more sustained epigenetic gene regulatory functions related to successful desensitization.

&lt;p&gt;We previously reported the results of a randomized, open-label trial of egg oral immunotherapy (OIT) in 50 children where 44% were desensitized and 46% were partially desensitized after 8 months of treatment. Here we focus on cell-mediated molecular mechanisms driving desensitization during egg OIT. We sought to determine whether changes in genome-wide gene expression in blood cells during egg OIT correlate with humoral responses and the clinical outcome. The blood cell transcriptome of 50 children receiving egg OIT was profiled using peripheral blood mononuclear cell (PBMC) samples obtained at baseline and after 3 and 8 months of OIT. We identified 467 differentially expressed genes (DEGs) after 3 or 8 months of egg OIT. At 8 months, 86% of the DEGs were downregulated and played a role in the signaling of TREM1, IL-6, and IL-17. In correlation analyses, Gal d 1–4-specific IgG4 antibodies associated positively with DEGs playing a role in pathogen recognition and antigen presentation and negatively with DEGs playing a role in the signaling of IL-10, IL-6, and IL-17. Desensitized and partially desensitized patients had differences in their antibody responses, and although most of the transcriptomic changes were shared, both groups had also specific patterns, which suggest slower changes in partially desensitized and activation of NK cells in the desensitized group. OIT for egg allergy in children inhibits inflammation and activates innate immune responses regardless of the clinical outcome at 8 months. Changes in gene expression patterns first appear as posttranslational protein modifications, followed by more sustained epigenetic gene regulatory functions related to successful desensitization.&lt;/p&gt;

We previously reported the results of a randomized, open-label trial of egg oral immunotherapy (OIT) in 50 children where 44% were desensitized and 46% partially desensitized after 8 months of treatment. Here, we focus on cell-mediated molecular mechanisms driving desensitization during egg OIT. We sought to determine whether changes in genome-wide gene expression in blood cells during egg OIT correlate with humoral responses and the clinical outcome. The blood cell transcriptome of 50 children receiving egg OIT was profiled using peripheral blood mononuclear cell (PBMC) samples obtained at baseline and after 3 and 8 months of OIT. We identified 467 differentially expressed genes (DEGs) after 3 or 8 months of egg OIT. At 8 months, 86% of the DEGs were downregulated and played a role in the signaling of TREM1, IL-6, and IL-17. In correlation analyses, Gal d 1-4 –specific IgG4 antibodies associated positively with DEGs playing a role in pathogen recognition and antigen presentation, and negatively with DEGs playing a role in the signaling of IL-10, IL-6, and IL-17. Desensitized and partially desensitized patients had differences in their antibody responses, and although most of the transcriptomic changes were shared, both groups had also specific patterns, which suggest slower changes in partially desensitized and activation of NK cells in the desensitized group. OIT for egg allergy in children inhibits inflammation and activates innate immune responses regardless of the clinical outcome at 8 months. Changes in gene expression patterns first appear as posttranslational protein modifications, followed by more sustained epigenetic gene regulatory functions related to successful desensitization.

We previously reported the results of a randomized, open-label trial of egg oral immunotherapy (OIT) in 50 children where 44% were desensitized and 46% were partially desensitized after 8 months of treatment. Here we focus on cell-mediated molecular mechanisms driving desensitization during egg OIT. We sought to determine whether changes in genome-wide gene expression in blood cells during egg OIT correlate with humoral responses and the clinical outcome. The blood cell transcriptome of 50 children receiving egg OIT was profiled using peripheral blood mononuclear cell (PBMC) samples obtained at baseline and after 3 and 8 months of OIT. We identified 467 differentially expressed genes (DEGs) after 3 or 8 months of egg OIT. At 8 months, 86% of the DEGs were downregulated and played a role in the signaling of TREM1, IL-6, and IL-17. In correlation analyses, Gal d 1–4-specific IgG4 antibodies associated positively with DEGs playing a role in pathogen recognition and antigen presentation and negatively with DEGs playing a role in the signaling of IL-10, IL-6, and IL-17. Desensitized and partially desensitized patients had differences in their antibody responses, and although most of the transcriptomic changes were shared, both groups had also specific patterns, which suggest slower changes in partially desensitized and activation of NK cells in the desensitized group. OIT for egg allergy in children inhibits inflammation and activates innate immune responses regardless of the clinical outcome at 8 months. Changes in gene expression patterns first appear as posttranslational protein modifications, followed by more sustained epigenetic gene regulatory functions related to successful desensitization.

&lt;p&gt;We previously reported the results of a randomized, open-label trial of egg oral immunotherapy (OIT) in 50 children where 44% were desensitized and 46% were partially desensitized after 8 months of treatment. Here we focus on cell-mediated molecular mechanisms driving desensitization during egg OIT. We sought to determine whether changes in genome-wide gene expression in blood cells during egg OIT correlate with humoral responses and the clinical outcome. The blood cell transcriptome of 50 children receiving egg OIT was profiled using peripheral blood mononuclear cell (PBMC) samples obtained at baseline and after 3 and 8 months of OIT. We identified 467 differentially expressed genes (DEGs) after 3 or 8 months of egg OIT. At 8 months, 86% of the DEGs were downregulated and played a role in the signaling of TREM1, IL-6, and IL-17. In correlation analyses, Gal d 1–4-specific IgG4 antibodies associated positively with DEGs playing a role in pathogen recognition and antigen presentation and negatively with DEGs playing a role in the signaling of IL-10, IL-6, and IL-17. Desensitized and partially desensitized patients had differences in their antibody responses, and although most of the transcriptomic changes were shared, both groups had also specific patterns, which suggest slower changes in partially desensitized and activation of NK cells in the desensitized group. OIT for egg allergy in children inhibits inflammation and activates innate immune responses regardless of the clinical outcome at 8 months. Changes in gene expression patterns first appear as posttranslational protein modifications, followed by more sustained epigenetic gene regulatory functions related to successful desensitization.&lt;/p&gt;